|
End-of-day quote
Buenos Aires S.E.
18/08/2026
|
5-day change | 1st Jan Change | ||
| 20,170.00 ARS | +3.22% |
|
+0.05% | +7.92% |
| 02:29pm | GSK plc : Deutsche Bank remains Neutral | ZD |
| 18/08 | Chugai grants GSK exclusive global license for AID351 dengue antibody | AN |
| Market Cap | 7.57TCr 1,54,17900Cr 10TCr 8.83TCr 8.25TCr 14TCr 9,83900Cr 14TCr 97TCr 38TCr 4,93500Cr 39TCr 38TCr 16,31600Cr | P/E 2026 * |
14.3x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 9.49TCr 1,93,30900Cr 13TCr 11TCr 10TCr 18TCr 12,33700Cr 18TCr 1,22000Cr 48TCr 6,18700Cr 48TCr 47TCr 20,45700Cr | EV / Sales 2026 * |
2.79x | EV / Sales 2027 * | 2.59x |
| Free-Float |
92.75% | Yield 2026 * |
3.69% | Yield 2027 * | 3.97% |
Last Transcript: GSK plc
| 1 day | +3.22% | ||
| 1 week | +0.05% | ||
| Current month | -1.32% | ||
| 1 month | -1.47% | ||
| 3 months | +8.38% | ||
| 6 months | -8.94% | ||
| Current year | +7.92% |
| 1 week | 19,360 |  | 20,270 |
| 1 month | 19,360 | | 22,300 |
| Current year | 17,020 | | 22,760 |
| 1 year | 12,975 | | 22,760 |
| 3 years | 6,390 | | 22,760 |
| 5 years | 2,171.5 | | 22,760 |
| 10 years | 543.12 | | 22,760 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 06/05/2026 |
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.22% | +0.05% | - | - | 10TCr | |
| +3.98% | +3.97% | +80.42% | +130.65% | 1,09300Cr | |
| +0.91% | +4.58% | +53.44% | +63.02% | 65TCr | |
| +2.28% | +5.94% | +27.81% | +75.50% | 46TCr | |
| +1.80% | +0.52% | +41.20% | +44.48% | 35TCr | |
| +1.24% | +2.35% | +25.99% | +41.24% | 29TCr | |
| +2.07% | +2.97% | +2.27% | +12.89% | 25TCr | |
| +3.76% | +5.43% | +48.46% | +68.30% | 23TCr | |
| +1.05% | -0.02% | -13.96% | -52.51% | 20TCr | |
| +3.12% | +8.52% | +24.97% | +94.15% | 18TCr | |
| Average | +2.28% | +1.20% | +32.29% | +53.08% | 41.23TCr | |
| Weighted average by Cap. | +2.42% | +1.45% | +46.10% | +73.13% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.39TCr 69,17400Cr 4.62TCr 3.96TCr 3.7TCr 6.38TCr 4,41500Cr 6.49TCr 44TCr 17TCr 2,21400Cr 17TCr 17TCr 7,32100Cr | 3.55TCr 72,43000Cr 4.84TCr 4.15TCr 3.87TCr 6.68TCr 4,62200Cr 6.79TCr 46TCr 18TCr 2,31800Cr 18TCr 18TCr 7,66500Cr |
| Net income | 543.57Cr 11,07800Cr 739.66Cr 634.48Cr 592.46Cr 1.02TCr 71TCr 1.04TCr 6.99TCr 2.74TCr 35TCr 2.78TCr 2.72TCr 1,17200Cr | 648.43Cr 13,21500Cr 882.35Cr 756.88Cr 706.75Cr 1.22TCr 84TCr 1.24TCr 8.34TCr 3.27TCr 42TCr 3.31TCr 3.24TCr 1,39800Cr |
| Net Debt | 1.92TCr 39,13000Cr 2.61TCr 2.24TCr 2.09TCr 3.61TCr 2,49700Cr 3.67TCr 25TCr 9.67TCr 1,25200Cr 9.81TCr 9.6TCr 4,14100Cr | 1.64TCr 33,36800Cr 2.23TCr 1.91TCr 1.78TCr 3.08TCr 2,13000Cr 3.13TCr 21TCr 8.25TCr 1,06800Cr 8.37TCr 8.18TCr 3,53100Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/26/18 | ARS 20,170.00 | +3.22% | 689 |
| 14/26/14 | ARS 19,540.00 | -1.91% | 642 |
| 13/26/13 | ARS 19,920.00 | -0.15% | 236 |
| 12/26/12 | ARS 19,950.00 | -1.04% | 1,047 |
| 11/26/11 | ARS 20,160.00 | -2.18% | 296 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
